Innovation in immunomodulation

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is  developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.